Daniel L. Menezes

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 248 citations · Full text

2,4-Bismorpholino 6-Heterocyclic Pyrimidines, Pi3 Kinase Inhibitor, Orally Bioavailable Class +18

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Lorenzo Falchi, Helen Ma, Sandra E. Klein et al. · Blood · 2020 · 174 citations · Full text

<i>In vivo</i> Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Sang Hoon Lee, Daniel L. Menezes, Jayesh Vora et al. · Clinical Cancer Research · 2005 · 173 citations

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue et al. · Blood · 2019 · 127 citations · Full text